Search Results - "Michalis, Eurydiki"

High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents by Terpos, Evangelos, Katodritou, Eirini, Roussou, Maria, Pouli, Anastasia, Michalis, Eurydiki, Delimpasi, Sosana, Parcharidou, Agapi, Kartasis, Zafiris, Zomas, Athanasios, Symeonidis, Argiris, Viniou, Nora-Athina, Anagnostopoulos, Nikolaos, Economopoulos, Theofanis, Zervas, Konstantinos, Dimopoulos, Meletios A.

“…Objectives:  High serum lactate dehydrogenase (LDH) is associated with features of advanced disease and inferior survival in multiple myeloma. It is however…”
Get full text

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group by Katodritou, Eirini, Terpos, Evangelos, Delimpasi, Sossana, Kotsopoulou, Maria, Michalis, Eurydiki, Vadikolia, Chrysanthi, Kyrtsonis, Marie-Christine, Symeonidis, Argiris, Giannakoulas, Nikolaos, Vadikolia, Chrissa, Michael, Michalis, Kalpadakis, Christina, Gougopoulou, Theodora, Prokopiou, Chrystalla, Kaiafa, Georgia, Christoulas, Dimitrios, Gavriatopoulou, Maria, Giannopoulou, Evlampia, Labropoulou, Vasiliki, Verrou, Evgenia, Kastritis, Efstathios, Konstantinidou, Pavlina, Anagnostopoulos, Achilles, Dimopoulos, Meletios A.

“…We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty…”
Get full text

A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement by Papanastasiou, Labrini, Skarakis, Nikitas, Vardaka, Maria, Dimitriadi, Anastasia, Lampropoulou, Pinelopi, Perpinia, Anastasia, Vidalakis, Eleftherios, Choreftaki, Theodosia, Marinakis, Theodoros, Kounadi, Theodora, Vatalas, Ioannis-Anastasios, Michalis, Eurydiki

“…We report an extremely rare case of extranodal B-cell NHL: DLBCL (diffuse large B-cell non-Hodgkin lymphoma), stage IVE, presenting with heart and bilateral…”
Get full text

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience by Angelopoulou, Maria K., Vassilakopoulos, Theodoros P., Batsis, Ioannis, Sakellari, Ioanna, Gkirkas, Konstantinos, Pappa, Vasiliki, Giannoulia, Panagiota, Apostolidis, Ioannis, Apostolopoulos, Christos, Roussou, Paraskevi, Panayiotidis, Panayiotis, Dimou, Maria, Kyrtsonis, Marie‐Christine, Palassopoulou, Maria, Vassilopoulos, Georgios, Moschogiannis, Maria, Kalpadakis, Christina, Margaritis, Dimitrios, Spyridonidis, Alexander, Michalis, Eurydiki, Anargyrou, Konstantinos, Repousis, Panagiotis, Hatzimichael, Eleutheria, Bousiou, Zoi, Poulakidas, Elias, Grentzelias, Dimitrios, Harhalakis, Nikolaos, Pangalis, Gerassimos A., Anagnostopoulos, Achilles, Tsirigotis, Panagiotis

“…This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL)…”
Get full text

Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis by Tsirigotis, Panagiotis, Vassilakopoulos, Theodoros, Batsis, Ioannis, Bousiou, Zoi, Gkirkas, Konstantinos, Sakellari, Ioanna, Kaloyannidis, Panayotis, Roussou, Paraskevi, Pangalis, Gerassimos A., Moschogiannis, Maria, Vassilopoulos, George, Repousis, Panagiotis, Megalakaki, Aekaterini, Michalis, Eurydiki, Kalpadakis, Christina, Papadaki, Helen A., Kotsianidis, Ioannis, Hatzimichael, Eleftheria, Spyridonidis, Alexandros, Anargyrou, Konstantinos, Poulakidas, Elias, Giannoullia, Panagiota, Apostolidis, Ioannis, Stamouli, Maria, Konstantopoulos, Konstantinos, Pappa, Vassiliki, Panayiotidis, Panayiotis, Harhalakis, Nikolaos, Anagnostopoulos, Achilles, Angelopoulou, Maria

“…The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) after autologous stem cell transplantation (auto‐SCT) is poor. Recently,…”
Get full text

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration by Terpos, Evangelos, Katodritou, Eirini, Tsiftsakis, Evangelos, Kastritis, Efstathios, Christoulas, Dimitrios, Pouli, Anastasia, Michalis, Eurydiki, Verrou, Evgenia, Anargyrou, Konstantinos, Tsionos, Konstantinos, Dimopoulos, Meletios A, Zervas, Konstantinos

“…On behalf of the Greek Myeloma Study Group Correspondence: Evangelos Terpos, Department of Hematology and Medical Research, 251 General Air Force Hospital, 3…”
Get full text

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study by Terpos, Evangelos, Repousis, Panagiotis, Lalayanni, Chrysavgi, Hatjiharissi, Evdoxia, Assimakopoulou, Theodora, Vassilopoulos, Georgios, Pouli, Anastasia, Spanoudakis, Emmanouil, Michalis, Eurydiki, Pangalis, Gerassimos, Ntanasis-Stathopoulos, Ioannis, Poziopoulos, Christos, Kyrtsonis, Marie-Christine, Pappa, Vasiliki, Symeonidis, Argiris, Georgopoulos, Christos, Zikos, Panagiotis M, Gavriatopoulou, Maria, Papadaki, Helen A, Dadakaridou, Magdalini, Karvounis-Marolachakis, Kiki, Katodritou, Eirini

“…The "POWERFUL" multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy…”
Get full text

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy by Terpos, Evangelos, Christoulas, Dimitrios, Katodritou, Eirini, Bratengeier, Cornelia, Gkotzamanidou, Maria, Michalis, Eurydiki, Delimpasi, Sosana, Pouli, Anastasia, Meletis, John, Kastritis, Efstathios, Zervas, Konstantinos, Dimopoulos, Meletios A.

“…Sclerostin is a Wingless and Int‐1 inhibitor, which is produced by osteocytes and inhibits osteoblast‐driven bone formation. Sclerostin is implicated in the…”
Get full text

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years by Gavriatopoulou, Maria, García-Sanz, Ramón, Kastritis, Efstathios, Morel, Pierre, Kyrtsonis, Marie-Christine, Michalis, Eurydiki, Kartasis, Zafiris, Leleu, Xavier, Palladini, Giovanni, Tedeschi, Alessandra, Gika, Dimitra, Merlini, Giampaolo, Sonneveld, Pieter, Dimopoulos, Meletios A.

“…In this phase 2 multicenter trial, we evaluated the efficacy of the combination of bortezomib, dexamethasone, and rituximab (BDR) in 59 previously untreated…”
Get full text

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN) by Dimopoulos, Meletios A., García-Sanz, Ramón, Gavriatopoulou, Maria, Morel, Pierre, Kyrtsonis, Marie-Christine, Michalis, Eurydiki, Kartasis, Zafiris, Leleu, Xavier, Palladini, Giovanni, Tedeschi, Alessandra, Gika, Dimitra, Merlini, Giampaolo, Kastritis, Efstathios, Sonneveld, Pieter

“…In this phase 2 multicenter trial, we evaluated the activity of bortezomib, dexamethasone, and rituximab (BDR) combination in previously untreated symptomatic…”
Get full text

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis by Kastritis, Efstathios, Terpos, Evangelos, Roussou, Maria, Gavriatopoulou, Maria, Pamboukas, Constantinos, Boletis, Ioannis, Marinaki, Smaragda, Apostolou, Theofanis, Nikitas, Nikitas, Gkortzolidis, Georgios, Michalis, Eurydiki, Delimpasi, Sossana, Dimopoulos, Meletios A.

“…In this phase 1/2 study, we explored the feasibility and activity of an oral regimen of lenalidomide with low-dose dexamethasone and low-dose oral…”
Get full text

Identification of Very Low‐Risk Subgroups of Patients with Primary Mediastinal Large B‐Cell Lymphoma Treated with R‐CHOP by Vassilakopoulos, Theodoros P., Michail, Michail, Papageorgiou, Sotirios, Kourti, Georgia, Angelopoulou, Maria K., Panitsas, Fotios, Sachanas, Sotirios, Kalpadakis, Christina, Katodritou, Eirini, Leonidopoulou, Theoni, Kotsianidis, Ioannis, Hatzimichael, Eleftheria, Kotsopoulou, Maria, Dimou, Maria, Variamis, Eleni, Boutsis, Dimitrios, Terpos, Evangelos, Dimopoulou, Maria N., Karakatsanis, Stamatios, Michalis, Eurydiki, Karianakis, George, Tsirkinidis, Pantelis, Vadikolia, Chryssa, Poziopoulos, Christos, Pigaditou, Anna, Vrakidou, Effimia, Economopoulos, Theophanis, Kyriazopoulou, Lydia, Siakantaris, Marina P., Kyrtsonis, Marie‐Christine, Symeonidis, Argyris, Anargyrou, Konstantinos, Papaioannou, Maria, Hatjiharissi, Evdoxia, Vervessou, Elissavet, Tsirogianni, Maria, Palassopoulou, Maria, Gainaru, Gabriella, Stefanoudaki, Ekaterini, Zikos, Panayiotis, Tsirigotis, Panayiotis, Tsourouflis, Gerasimos, Assimakopoulou, Theodora, Konstantinidou, Pavlina, Papadaki, Helen, Megalakaki, Katerina, Dimopoulos, Meletios‐Athanasios, Pappa, Vassiliki, Karmiris, Themis, Roussou, Paraskevi, Panayiotidis, Panayiotis, Konstantopoulos, Kostas, Pangalis, Gerassimos A.

“…Background R‐CHOP can cure approximately 75% of patients with primary mediastinal large B‐cell lymphoma (PMLBCL), but prognostic factors have not been…”
Get full text

The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations? by Terpos, Evangelos, Christoulas, Dimitrios, Kastritis, Efstathios, Katodritou, Eirini, Pouli, Anastasia, Michalis, Eurydiki, Papassotiriou, Ioannis, Dimopoulos, Meletios A.

“…Objectives The estimation of glomerular filtration rate (eGFR) in multiple myeloma (MM) is based on equations that use serum creatinine (sCr), such as the…”
Get full text

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies by Zagouri, Flora, Kastritis, Efstathios, Zomas, Athanasios, Terpos, Evangelos, Katodritou, Eirini, Symeonidis, Argiris, Delimpasi, Sosana, Pouli, Anastasia, Vassilakopoulos, Theodoros P., Michalis, Eurydiki, Giannouli, Stavroula, Kartasis, Zafiris, Christoforidou, Anna, Kokoviadou, Kiriaki, Hatzimichael, Eleftheria, Gika, Dimitra, Megalakaki, Catherine, Papaioannou, Maria, Kyrtsonis, Marie‐Christine, Konstantopoulos, Kostas, Dimopoulos, Meletios A.

“…Objectives To evaluate the prognostic impact of hypercalcemia in newly diagnosed patients with symptomatic multiple myeloma (MM), especially after the…”
Get full text

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience by Katodritou, Eirini, Terpos, Evangelos, Kastritis, Efstathios, Delimpasis, Sossana, Symeonidis, Argiris S., Repousis, Panagiotis, Kyrtsonis, Marie-Christine, Vadikolia, Chrysa, Michalis, Eurydiki, Polychronidou, Genovefa, Michael, Michael, Papadaki, Sofia, Papathanasiou, Maria, Kokoviadou, Kyriaki, Kioumi, Anna, Vlachaki, Eythimia, Hadjiaggelidou, Christina, Kouraklis, Alexandra, Patsias, Ioannis, Gavriatopoulou, Maria, Kotsopoulou, Maria, Verrou, Evgenia, Gastari, Vasiliki, Christoulas, Dimitrios, Giannopoulou, Evlambia, Pouli, Anastasia, Konstantinidou, Pavlina, Anagnostopoulos, Achilles, Dimopoulos, Meletios-Athanasios

“…Involvement of the central nervous system (CNS) is a rare complication of multiple myeloma (MM). Herein, we have described the incidence, characteristics,…”
Get full text

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group by Terpos, Evangelos, Christoulas, Dimitrios, Kastritis, Efstathios, Katodritou, Eirini, Papatheodorou, Athanasios, Pouli, Anastasia, Kyrtsonis, Marie‐Christine, Michalis, Eurydiki, Papanikolaou, Xenophon, Gkotzamanidou, Maria, Koulieris, Efstathios, Gavriatopoulou, Maria, Zervas, Konstantinos, Dimopoulos, Meletios A.

“…The combination of lenalidomide plus dexamethasone (RD) is very effective for patients with relapsed/refractory myeloma. However, the effect of RD on bone…”
Get full text

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents by Terpos, Evangelos, Anargyrou, Konstantinos, Katodritou, Eirini, Kastritis, Efstathios, Papatheodorou, Athanasios, Christoulas, Dimitrios, Pouli, Anastasia, Michalis, Eurydiki, Delimpasi, Sosana, Gkotzamanidou, Maria, Nikitas, Nikitas, Koumoustiotis, Vasilios, Margaritis, Dimitrios, Tsionos, Konstantinos, Stefanoudaki, Ekaterini, Meletis, John, Zervas, Konstantinos, Dimopoulos, Meletios A.

“…The circulating levels of several angiogenic cytokines [angiopoietin‐1 (Ang‐1), angiopoietin‐2 (Ang‐2), vascular endothelial growth factor (VEGF), angiogenin…”
Get full text

Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents by Katodritou, Eirini, Terpos, Evangelos, Delimpasi, Sossana, Kotsopoulou, Maria, Michalis, Eurydiki, Vadikolia, Chrysanthi, Kyrtsonis, Marie-Christine, Symeonidis, Argiris, Giannakoulas, Nikolaos, Vadikolia, Chrissa, Michael, Michalis, Kalpadakis, Christina, Gougopoulou, Theodora, Prokopiou, Chrystalla, Kaiafa, Georgia D, Christoulas, Dimitrios, Gavriatopoulou, Maria, Giannopoulou, Evlampia, Lampropoulou, Vasiliki, Verrou, Evgenia, Kastritis, Efstathios, Konstantinidou, Pavlina, Anagnostopoulos, Achilles, Dimopoulos, Meletios A

“…Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder with poor outcome. We and others have previously demonstrated in a limited number of…”
Get full text

Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era by Dimopoulos, Meletios A., Kastritis, Efstathios, Delimpasi, Sossana, Katodritou, Eirini, Hatzimichael, Eleftheria, Kyrtsonis, Marie-Christine, Repousis, Panagiotis, Tsirogianni, Maria, Kartasis, Zafiris, Parcharidou, Agapi, Michael, Michalis, Michalis, Eurydiki, Tsatalas, Constantinos, Stefanoudaki, Ekaterini, Hatjiharissi, Eudoxia, Gika, Dimitra, Symeonidis, Argiris, Terpos, Evangelos, Zervas, Konstantinos

“…Background Multiple myeloma (MM) affects mainly elderly persons and because the population of octogenarians increases, it is common to treat patients ≥80 years…”
Get full text

The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation by Dimopoulos, Meletios A, Kastritis, Efstathios, Katodritou, Eirini, Pouli, Anastasia, Michalis, Eurydiki, Christoulas, Dimitrios, Gkotzamanidou, Maria, Papassotiriou, Ioannis, Zervas, Konstantinos, Terpos, Evangelos

“…Abstract 1849 Renal impairment (RI) is a frequent complication in multiple myeloma (MM). The estimation of glomerular filtration rate (GFR) is based on…”
Get full text